CureDuchenne Invests in ZappRx Platform to Streamline Specialty Prescribing...
Nonprofit invests in leading specialty prescription and prior authorization solution provider to get Duchenne patients breakthrough medications faster ZappRx Inc. a digital health company that...
View ArticleAcibadem Healthcare Group Pharmaceuticals Healthcare Deals and Alliances...
SummaryAcibadem Healthcare Group Acibadem is a healthcare service provider that provides diagnosis and treatment services. The center provides aesthetic plastic and reconstructive surgery; algology...
View ArticleGalapagos NV GLPG Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryGalapagos NV Galapagos is a biotechnology company that discovers and develops small molecule medicines. The company's clinical pipeline include filgotinib which is in Phase III clinical trials...
View ArticlePredictImmune Announces New Patent Grants and Allowances Across the UK EU and...
Patents cover PredictImmunes first family of intellectual property relating to methods for predicting autoimmune disease risk PredictImmune developers of pioneering prognostic tools for guiding...
View ArticleIncreased mortality in children with inflammatory bowel disease
Karolinska Institutet Children who develop inflammatory bowel disease ulcerative colitis or Crohn's disease have an increased risk of death both in childhood and later in life a study from Karolinska...
View ArticleuBiome Appoints Dr. Peter Turnbaugh PhD Associate Professor of Microbiology...
The leader in microbial genomics appoints professor and researcher with the G.W. Hooper Research Foundation at the University of California San Francisco to its board of scientific advisors.SAN...
View ArticleNSF awards $5 million grant to help scientists magnify societal impact of...
When Humira came on the market many found relief from symptoms of arthritis plaque psoriasis Crohns disease and ulcerative colitis.
View ArticleMorphoSys's Licensee Janssen has Reported That New TremfyaR Guselkumab 3Year...
DGAPNews MorphoSys AG Key words Study19.10.2018 1528 The issuer is solely responsible for the content of this announcement.PlaneggMunich Germany October 19 2018MorphoSys's Licensee Janssen has Reported...
View ArticleTheravance Biopharma Inc TBPH Financial and Strategic SWOT Analysis Review...
Theravance Biopharma Inc TBPH Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by...
View ArticleCrohns Subtype Accurately Predicted through miRNA Molecule...
Crohns Subtype Accurately Predicted through miRNA Molecule httpow.lydjfs30mfNBp pic.twitter.comfGCFJKVYLP
View ArticleNatco Pharma Ltd NATCOPHARM Pharmaceuticals Healthcare Deals and Alliances...
SummaryNatco Pharma Ltd Natco Pharma focuses on the research development manufacture and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosage...
View ArticleOncobiologics Inc ONS Pharmaceuticals Healthcare Deals and Alliances Profile...
SummaryOncobiologics Inc Oncobiologics is a clinical stage biopharmaceutical company that identifies develops manufactures and commercializes biosimilar therapeutics in the areas of immunology and...
View ArticleMedical News Today Cannabis relieves symptoms in Crohn's disease
Cannabis oil relieves symptoms and improves quality of life in people with Crohn's disease even though it has no impact on gut inflammation study reveals.
View ArticleFeedback expands its European customer base with new orders for TexRADÂ from...
Cambridge 22 October 2018 Feedback plc AIM FDBK "Feedback" or the "Company" the specialist medical imaging technology company announces that its operating company...
View ArticleuBiome Appoints Dr. Philip Bourne PhD Director of the Data Science Institute...
The leader in microbial genomics appoints acclaimed biomedical data scientist to its board of scientific advisors.SAN FRANCISCO PRWEB October 22 2018 uBiome the leader in microbial genomics announces...
View ArticleWith $50 Million in Upfront Money Takeda and Enterome DoubleDown on Crohns...
Two years after forging a partnership to collaborate on microbiome targets for gastrointestinal disorders Francebased Enterome SA and Takeda Pharmaceuticals have entered into a second agreement. This...
View ArticleWith $50 Million in Upfront Money Takeda and Enterome Double Down on Crohns...
Two years after forging a partnership to collaborate on microbiome targets for gastrointestinal disorders Francebased Enterome SA and Takeda Pharmaceuticals have entered into a second agreement. This...
View ArticleTakeda to CoDevelop Enterome Crohn's Disease Candidate EB8018
Takeda Pharmaceutical has agreed to license codevelop and copromote Enteromes lead candidate the Phase Ib Crohns disease candidate EB8018 Enterome said today through a collaboration that could generate...
View ArticleuBiome Appoints Kathie Swift MS RDN FAND Cofounder of the Integrative and...
The leader in microbial genomics appoints pioneer of cuttingedge nutrition programs to its board of scientific advisors.SAN FRANCISCO PRWEB October 23 2018 uBiome the leader in microbial genomics...
View Article